The rebound from COVID-19 created a huge tailwind for the world’s largest companies by revenue. Aggregate sales for the Fortune Global 500 hit $37.8 trillion, an increase of 19%—the highest annual growth rate in the list’s history.

Italian diagnostic firm DiaSorin on Wednesday reported a 32 percent year-over-year jump in revenues for the second quarter of 2022.

Following extraordinary demand for rapid COVID-19 antigen testing in 2021, Siemens Healthineers reported on Wednesday that the company's fiscal third quarter COVID-19 testing revenue declined sharply

Qiagen on Tuesday afternoon reported strong year-over-year sales growth in its core non-COVID-related product portfolio, prompting the company to raise its full-year revenue and earnings guidance even as its COVID-19-related business remains volatile.

Roche on Thursday reported its Diagnostics division revenues grew 10 percent year over year in the first half of the year but said that it expects the momentum from COVID-19 testing-related sales to slow throughout the rest of the year.

Chinese precision oncology firm Burning Rock Biotech reported on Tuesday that its first quarter 2022 revenues were up 27 percent year over year.

Agilent Technologies reported after the close of the market on Tuesday that its fiscal second quarter revenues rose 5 percent year over year.

Castle Biosciences reported after the close of the market on Monday that its first quarter revenues increased 18 percent year over year.

DiaSorin said on Friday that its first quarter revenues rose 34 percent year over year.

On April 28, YHLO (688575. SH) released its annual performance report for 2021. From January 1 to December 31, 2021, the company achieved an operating revenue of 1.178 billion CNY, a year-on-year increase of 17.91%, a net profit of 205 million CNY, a year-on-year decrease of 2.75%.